[HTML][HTML] Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04
L Zhang, X Xie, H Luo, R Qian, Y Yang, H Yu, J Huang… - Cell Discovery, 2024 - nature.com
Drug resistance poses a significant challenge in the development of effective therapies
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04.
L Zhang, X Xie, H Luo, R Qian, Y Yang, H Yu… - Cell …, 2024 - europepmc.org
Drug resistance poses a significant challenge in the development of effective therapies
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04
L Zhang, X Xie, H Luo, R Qian, Y Yang… - Cell …, 2024 - pubmed.ncbi.nlm.nih.gov
Drug resistance poses a significant challenge in the development of effective therapies
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04
L Zhang, X Xie, H Luo, H Yu, J Huang, PY Shi, Q Hu - bioRxiv, 2023 - biorxiv.org
Drug resistance poses a significant challenge in the development of effective therapies
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04.
L Zhang, X Xie, H Luo, R Qian, Y Yang, H Yu… - Cell …, 2024 - search.ebscohost.com
Drug resistance poses a significant challenge in the development of effective therapies
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …
[HTML][HTML] Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04
L Zhang, X Xie, H Luo, R Qian, Y Yang, H Yu… - Cell …, 2024 - ncbi.nlm.nih.gov
Drug resistance poses a significant challenge in the development of effective therapies
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04.
L Zhang, X Xie, H Luo, R Qian, Y Yang, H Yu… - Cell …, 2024 - europepmc.org
Drug resistance poses a significant challenge in the development of effective therapies
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …